Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators.

Lancet. 2019 Dec 5. pii: S0140-6736(19)33041-7. doi: 10.1016/S0140-6736(19)33041-7. [Epub ahead of print]

PMID:
31813633
2.

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease.

Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, Fusaro E, Saracco GM, Bugianesi E, Astegiano M.

J Clin Med. 2019 Oct 9;8(10). pii: E1646. doi: 10.3390/jcm8101646.

3.

qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.

Liu F, Goh GB, Tiniakos D, Wee A, Leow WQ, Zhao JM, Rao HY, Wang XX, Wang Q, Wan WK, Lim KH, Romero-Gomez M, Petta S, Bugianesi E, Tan CK, Harrison SA, Anstee QM, Jason Chang PE, Wei L.

Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986. [Epub ahead of print]

PMID:
31600834
4.

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.

Chen F, Esmaili S, Rogers G, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M.

Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]

PMID:
31442319
5.

Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.

Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E.

J Hepatol. 2019 Nov;71(5):1012-1021. doi: 10.1016/j.jhep.2019.06.031. Epub 2019 Jul 10.

PMID:
31301321
6.

In Memoriam: Valerio Nobili (1966-2019).

Bugianesi E, Pinzani M.

J Hepatol. 2019 Jun 8. pii: S0168-8278(19)30281-8. doi: 10.1016/j.jhep.2019.05.002. [Epub ahead of print] No abstract available.

PMID:
31186123
7.

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.

Petta S, Wai-Sun Wong V, Bugianesi E, Fracanzani AL, Cammà C, Hiriart JB, Lai-Hung Wong G, Vergniol J, Wing-Hung Chan A, Giannetti A, Merrouche W, Lik-Yuen Chan H, Le-Bail B, Lombardi R, Guastella S, Craxì A, de Ledinghen V.

Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153.

PMID:
31169533
8.

Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study.

Rosso C, Caviglia GP, Ciruolo M, Ciancio A, Younes R, Olivero A, Giordanino C, Troshina G, Abate ML, Rizzetto M, Pellicano R, Saracco GM, Bugianesi E, Smedile A.

Minerva Med. 2019 Oct;110(5):401-409. doi: 10.23736/S0026-4806.19.06108-1. Epub 2019 May 6.

PMID:
31081312
9.

Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation.

Delogu W, Caligiuri A, Provenzano A, Rosso C, Bugianesi E, Coratti A, Macias-Barragan J, Galastri S, Di Maira G, Marra F.

Dig Liver Dis. 2019 Oct;51(10):1400-1408. doi: 10.1016/j.dld.2019.03.002. Epub 2019 Apr 18.

PMID:
31005555
10.

Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States.

Golabi P, Paik J, Reddy R, Bugianesi E, Trimble G, Younossi ZM.

BMC Gastroenterol. 2019 Apr 16;19(1):56. doi: 10.1186/s12876-019-0972-6.

11.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC.

Sci Rep. 2019 Mar 6;9(1):3682. doi: 10.1038/s41598-019-39998-2.

12.

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms.

Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, Abate ML, Irving WL, Sheridan D, Dore GJ, Spengler U, Lampertico P, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Santoro R, Gallego-Durán R, Fischer J, Nattermann J, D'Ambrosio R, McLeod D, Powell E, Latchoumanin O, Thabet K, Najim MAM, Douglas MW, Liddle C, Qiao L, George J, Eslam M; International Liver Disease Genetics Consortium (ILDGC).

Sci Rep. 2019 Feb 5;9(1):1439. doi: 10.1038/s41598-018-35736-2.

13.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

PMID:
30708111
14.

NASH in Lean Individuals.

Younes R, Bugianesi E.

Semin Liver Dis. 2019 Feb;39(1):86-95. doi: 10.1055/s-0038-1677517. Epub 2019 Jan 17. Review.

PMID:
30654392
15.

A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD.

Younes R, Bugianesi E.

Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):80-82. doi: 10.1038/s41575-018-0094-6. Review. No abstract available.

PMID:
30559444
16.

Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.

Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M, Castellanos-Fernandez M, George J, Jacobson IM, Bugianesi E, Wong VW, Arrese M, de Ledinghen V, Romero-Gomez M, Mendez-Sanchez N, Ahmed A, Wong R, Papatheodoridis G, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A; Global NASH Council.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1625-1633.e1. doi: 10.1016/j.cgh.2018.11.033. Epub 2018 Nov 23.

PMID:
30476585
17.

A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.

Metwally M, Bayoumi A, Romero-Gomez M, Thabet K, John M, Adams LA, Huo X, Aller R, García-Monzón C, Teresa Arias-Loste M, Bugianesi E, Miele L, Gallego-Durán R, Fischer J, Berg T, Liddle C, Qiao L, George J, Eslam M.

J Hepatol. 2019 Mar;70(3):494-500. doi: 10.1016/j.jhep.2018.10.021. Epub 2018 Oct 31.

PMID:
30389552
18.

An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers.

Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, Bianchi G, Marchesini G.

J Hepatol. 2018 Nov;69(5):1155-1163. doi: 10.1016/j.jhep.2018.07.013. Epub 2018 Oct 2.

19.

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB.

Hepatology. 2019 Jun;69(6):2672-2682. doi: 10.1002/hep.30251. Review.

PMID:
30179269
20.

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A; Global Nonalcoholic Steatohepatitis Council.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3. doi: 10.1016/j.cgh.2018.05.057. Epub 2018 Jun 14.

PMID:
29908364
21.

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease.

Dongiovanni P, Meroni M, Mancina RM, Baselli G, Rametta R, Pelusi S, Männistö V, Fracanzani AL, Badiali S, Miele L, Grimaudo S, Petta S, Bugianesi E, Soardo G, Fargion S, Pihlajamäki J, Romeo S, Valenti L.

Hepatol Commun. 2018 Apr 25;2(6):666-675. doi: 10.1002/hep4.1192. eCollection 2018 Jun.

22.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

Petta S, Sebastiani G, Bugianesi E, Viganò M, Wong VW, Berzigotti A, Fracanzani AL, Anstee QM, Marra F, Barbara M, Calvaruso V, Cammà C, Di Marco V, Craxì A, de Ledinghen V.

J Hepatol. 2018 Oct;69(4):878-885. doi: 10.1016/j.jhep.2018.05.019. Epub 2018 May 24.

PMID:
29802949
23.

Reply to "Definition of Small for Gestational Age and Low Birthweight".

Nobili V, Mosca A, Bugianesi E.

Am J Gastroenterol. 2018 Mar;113(3):442. doi: 10.1038/ajg.2018.2. No abstract available.

PMID:
29535437
24.

Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein.

Morello E, Sutti S, Foglia B, Novo E, Cannito S, Bocca C, Rajsky M, Bruzzì S, Abate ML, Rosso C, Bozzola C, David E, Bugianesi E, Albano E, Parola M.

Hepatology. 2018 Jun;67(6):2196-2214. doi: 10.1002/hep.29754. Epub 2018 Apr 19.

25.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K.

Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.

26.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K.

Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724.

27.

Reply.

Gaggini M, Bugianesi E, Gastaldelli A.

Hepatology. 2018 Mar;67(3):1178-1180. doi: 10.1002/hep.29699. Epub 2018 Jan 30. No abstract available.

28.

Should we undertake surveillance for HCC in patients with NAFLD?

Younes R, Bugianesi E.

J Hepatol. 2018 Feb;68(2):326-334. doi: 10.1016/j.jhep.2017.10.006. Epub 2017 Nov 6. Review.

PMID:
29122695
29.

Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study.

Younes R, Rosso C, Petta S, Cucco M, Marietti M, Caviglia GP, Ciancio A, Abate ML, Cammà C, Smedile A, Craxì A, Saracco GM, Bugianesi E.

Liver Int. 2018 Apr;38(4):715-723. doi: 10.1111/liv.13612. Epub 2017 Nov 3.

30.

Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents.

Ciancio A, Bosio R, Bo S, Pellegrini M, Sacco M, Vogliotti E, Fassio G, Bianco Mauthe Degerfeld AGF, Gallo M, Giordanino C, Terzi di Bergamo L, Ribaldone D, Bugianesi E, Smedile A, Rizzetto M, Saracco GM.

J Med Virol. 2018 Feb;90(2):320-327. doi: 10.1002/jmv.24954. Epub 2017 Nov 14.

PMID:
28960353
31.

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E.

Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20. Review.

PMID:
28930295
32.

Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.

Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, Abate ML, Gambino R, Cassader M, Bugianesi E, Gastaldelli A.

Hepatology. 2018 Jan;67(1):145-158. doi: 10.1002/hep.29465. Epub 2017 Nov 17.

PMID:
28802074
33.

Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas.

Soverini V, Persico M, Bugianesi E, Forlani G, Salamone F, Masarone M, La Mura V, Mazzotti A, Bruno A, Marchesini G.

Acta Diabetol. 2017 Sep;54(9):887. doi: 10.1007/s00592-017-1032-8. No abstract available.

PMID:
28756473
34.

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, Walker L, Baselli G, Pelusi S, Rosso C, Vanni E, Daly A, Mancina RM, Grieco A, Miele L, Grimaudo S, Craxi A, Petta S, De Luca L, Maier S, Soardo G, Bugianesi E, Colli F, Romagnoli R, Anstee QM, Reeves HL, Fracanzani AL, Fargion S, Romeo S, Valenti L.

Cancer Med. 2017 Aug;6(8):1930-1940. doi: 10.1002/cam4.1078. Epub 2017 Jul 4.

35.

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L.

Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0.

36.

Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.

Isokuortti E, Zhou Y, Peltonen M, Bugianesi E, Clement K, Bonnefont-Rousselot D, Lacorte JM, Gastaldelli A, Schuppan D, Schattenberg JM, Hakkarainen A, Lundbom N, Jousilahti P, Männistö S, Keinänen-Kiukaanniemi S, Saltevo J, Anstee QM, Yki-Järvinen H.

Diabetologia. 2017 Oct;60(10):1873-1882. doi: 10.1007/s00125-017-4340-1. Epub 2017 Jun 29.

PMID:
28660493
37.

Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease.

Bugianesi E, Bizzarri C, Rosso C, Mosca A, Panera N, Veraldi S, Dotta A, Giannone G, Raponi M, Cappa M, Alisi A, Nobili V.

Am J Gastroenterol. 2017 Aug;112(8):1277-1286. doi: 10.1038/ajg.2017.140. Epub 2017 May 30.

38.

IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.

Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D, Grønbæk H, Abate ML, Hartmann R, Bugianesi E, Spengler U, Rojas A, Booth DR, Weltman M, Mollison L, Cheng W, Riordan S, Mahajan H, Fischer J, Nattermann J, Douglas MW, Liddle C, Powell E, Romero-Gomez M, George J; International Liver Disease Genetics Consortium (ILDGC).

Nat Genet. 2017 May;49(5):795-800. doi: 10.1038/ng.3836. Epub 2017 Apr 10.

PMID:
28394349
39.

Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis.

Cannito S, Morello E, Bocca C, Foglia B, Benetti E, Novo E, Chiazza F, Rogazzo M, Fantozzi R, Povero D, Sutti S, Bugianesi E, Feldstein AE, Albano E, Collino M, Parola M.

PLoS One. 2017 Mar 1;12(3):e0172575. doi: 10.1371/journal.pone.0172575. eCollection 2017.

40.

Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study.

Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, Porzio M, Rosso C, Fargion S, George J, Craxì A.

Liver Int. 2017 Sep;37(9):1389-1396. doi: 10.1111/liv.13397. Epub 2017 Mar 13.

41.

An extended fatty liver index to predict non-alcoholic fatty liver disease.

Kantartzis K, Rettig I, Staiger H, Machann J, Schick F, Scheja L, Gastaldelli A, Bugianesi E, Peter A, Schulze MB, Fritsche A, Häring HU, Stefan N.

Diabetes Metab. 2017 Jun;43(3):229-239. doi: 10.1016/j.diabet.2016.11.006. Epub 2017 Jan 12.

42.

Pathophysiology of Non Alcoholic Fatty Liver Disease.

Petta S, Gastaldelli A, Rebelos E, Bugianesi E, Messa P, Miele L, Svegliati-Baroni G, Valenti L, Bonino F.

Int J Mol Sci. 2016 Dec 11;17(12). pii: E2082. Review.

43.

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.

McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM.

Am J Gastroenterol. 2017 May;112(5):740-751. doi: 10.1038/ajg.2016.453. Epub 2016 Oct 11.

44.

Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014.

Saracco GM, Evangelista A, Fagoonee S, Ciccone G, Bugianesi E, Caviglia GP, Abate ML, Rizzetto M, Pellicano R, Smedile A.

World J Gastroenterol. 2016 Sep 28;22(36):8187-93. doi: 10.3748/wjg.v22.i36.8187.

45.

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.

Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, Craxi A, Bugianesi E, Fargion S, Valenti L.

PLoS One. 2016 Sep 20;11(9):e0163069. doi: 10.1371/journal.pone.0163069. eCollection 2016.

46.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Grønbæk H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengler U, Nattermann J, Wahid A, Rojas A, White R, Douglas MW, McLeod D, Powell E, Liddle C, van der Poorten D, George J, Eslam M; International Liver Disease Genetics Consortium.

Nat Commun. 2016 Sep 15;7:12757. doi: 10.1038/ncomms12757.

47.

Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists.

Polyzos SA, Bugianesi E, Kountouras J, Mantzoros CS.

Metabolism. 2017 Jan;66:64-68. doi: 10.1016/j.metabol.2016.08.001. Epub 2016 Aug 9. No abstract available.

48.

[Non-alcoholic fatty liver disease (NAFLD)].

Bugianesi E, Marietti M.

Recenti Prog Med. 2016 Jul;107(7):360-8. doi: 10.1701/2318.24928. Italian.

49.

Undernutrition, risk of malnutrition and obesity in gastroenterological patients: A multicenter study.

Rizzi M, Mazzuoli S, Regano N, Inguaggiato R, Bianco M, Leandro G, Bugianesi E, Noè D, Orzes N, Pallini P, Petroni ML, Testino G, Guglielmi FW.

World J Gastrointest Oncol. 2016 Jul 15;8(7):563-72. doi: 10.4251/wjgo.v8.i7.563.

50.

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T; FLIP Consortium and the FibroFrance Group.

Aliment Pharmacol Ther. 2016 Oct;44(8):877-89. doi: 10.1111/apt.13770. Epub 2016 Aug 23.

Supplemental Content

Loading ...
Support Center